E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
inflammatory bowel disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045365 |
E.1.2 | Term | Ulcerative colitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To assess the effect of BMS-986165 on clinical remission at the end of the induction period
- To assess the safety and tolerability of BMS-986165 in subjects with moderate to severe UC |
|
E.2.2 | Secondary objectives of the trial |
- To assess the effect of BMS-986165 on clinical response through the end of the induction period
- To assess the effect of BMS 986165 on endoscopic response at the end of the induction period
- To assess the effect of BMS-986165 on endoscopic remission at the end of the induction period |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
a) Documented diagnosis (endoscopic and histological) of UC at least 12 weeks prior to screening
b) Disease severity: moderate to severe active UC defined as an Adapted Mayo Score of 5 to 9 points, inclusive, that includes all of the following subscore values:
• An endoscopic subscore of ≥ 2 (screening endoscopy)
• A rectal bleeding subscore ≥ 1
• A stool frequency subscore of ≥ 2
c) Active UC extending ≥ 15 cm from the anal verge and confirmed by a screening/baseline colonoscopy/sigmoidoscopy prior to the randomization visit
d) Documentation of an inadequate response, loss of response, or intolerance to a treatment course of 1 or more of the following standard of care medications:
• 5- ASAs, such as mesalamine, sulfasalazine, olsalazine, or balsalazide
• CS, such as prednisone (or equivalent) or budesonide (or equivalent)
• Immunosuppressants, such as azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX)
• Anti-tumor necrosis factor (TNF)-α agents, such as infliximab, adalimumab, or golimumab
• Integrin inhibitor, such as vedolizumab
Subjects currently using concomitant salicylates, probiotics, or oral CS (≤ 20 mg prednisone or equivalent, ≤ 9 mg budesonide or equivalent) at stable doses prior to the randomization visit are eligible provided they are on stable doses for the specified time period.
|
|
E.4 | Principal exclusion criteria |
a) Previous/current documented diagnosis of CD, indeterminate colitis, ischemic colitis, pseudomembranous colitis.
b) Current or recent evidence of fulminant colitis, abdominal abscess, toxic megacolon, or bowel perforation.
c) History or evidence of any extensive colonic resection, subtotal or total colectomy, with or without presence of a stoma or ileoanal pouch.
d) History of diverticulitis within 60 days prior to the randomization visit
e) Current colonic adenomas or dysplasia or past confirmed colonic dysplasia that has not been eradicated. A subject with prior history of adenomatous polyps will be eligible if the polyps have been completely removed (documented) and the subject is free of polyps at baseline.
f) Current or recent gastrointestinal disease, including gastrointestinal surgery, that could impact the absorption of study treatment, or current or recent gastrointestinal resections.
g) Women who are pregnant or breastfeeding.
h) Any major illness/condition or evidence of an unstable clinical condition, or local active infection/infectious
i) Any major surgery (requiring general anesthesia) within the last 30 days prior to the randomization visit
j) History of bleeding disorders or recent use of anti-platelet or anti-thrombotic agents that in the investigator’s judgment preclude safely performing endoscopic procedures and biopsy
k) Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
l) Class III or IV congestive heart failure, as classified by the New York Heart Association (NYHA) Functional Classification or any recent onset of heart failure resulting in NYHA Class III/IV symptoms.
m) Acute coronary syndrome and/or any history of significant cerebrovascular disease within 24 weeks before screening.
n) Female subjects with a breast cancer screen suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded
o) Significant blood loss (> 500 mL) or blood transfusion within 4 weeks prior to the randomization visit.
p) Inability to tolerate oral medication.
q) Inability to undergo venipuncture and/or tolerate venous access.
r) Drug or alcohol abuse.
s) Inability to comply with restrictions and prohibited treatments, as listed in Section 6.7.
t) Previous exposure to BMS-986165/ TYK2 inhibitors in any study.
u) Prior lack of response to anti-12/23 p40 antibodies or anti-IL-23 p19 antibodies
v) Failure or loss of response to JAK inhibitors
w) Nonresponders to > 2 biologic agents for the treatment of UC.
x) Use of other investigational agents within 12 weeks or 5 half-lives, whichever is longer, prior to the randomization visit.
y) Use of topical rectal treatment with 5-ASA or CS within 2 weeks prior randomization visit.
z) Current use of CS at a dose of > 20 mg/day for prednisone or equivalent or > 9 mg/day for budesonide or equivalent.
aa) Use of immunosuppressants within 4 weeks prior to the randomization visit.
bb) Use of a biologic agent within 8 weeks or 5 half-lives, whichever is longer, prior to the randomization visit
cc) Previous stem cell transplantation
dd) Receipt of either lymphocyte apheresis or selective monocyte, granulocyte apheresis (eg, Cellosobra®) is prohibited within 12 months prior to the randomization visit.
ee) Use of therapeutic enema or suppository, other than required for ileocolonoscopy, within 7 days prior to the randomization visit.
ff) Receipt of tube feeding, defined formula diets, or total parenteral alimentation.
gg) Evidence of active or latent tuberculosis (TB), as an indeterminate IGRA result at screening with no signs or symptoms of active TB
hh) Evidence of, or positive test for, hepatitis B virus (HBV)
ii) Evidence of, or positive test for, hepatitis C virus (HCV). A positive test for HCV is defined as:
jj) Positive for human immunodeficiency virus (HIV) by antibody testing (HIV-1 and 2 Ab) at screening.
kk) Currently on any therapy for chronic infection History of congenital or acquired immunodeficiency.
ll) Known active infection, or any major episode of infection requiring hospitalization or treatment with parenteral (intramuscular or intravenous [IV]) antimicrobial agents
mm) Previous history of herpes zoster, herpes simplex, or influenza infection within 12 weeks before the first dose of study treatment
nn) Administration of a live vaccine within 90 days or an inactivated vaccine within 30 days before the first dose of study treatment administration.
oo) Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, chest x-ray, or clinical laboratory determinations beyond what is consistent with the target population
pp) Clinically significant abnormalities on chest x-ray or ECG
qq) Clinically significant abnormalities in laboratory testing
rr) Positive stool culture for enteric pathogens (ova + parasites [O+P], bacteria) or positive for C. difficile at screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Clinical remission per Adapted Mayo Score |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Clinical response
• Endoscopic response
• Endoscopic remission
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 38 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Canada |
Czech Republic |
Germany |
Hungary |
Italy |
Japan |
Korea, Republic of |
Poland |
Russian Federation |
Spain |
Switzerland |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial is defined as the last scheduled procedure shown in the Schedule of Activities for the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |